Excuse me, this is the conference coordinator. I’d like to thank everyone for holding for today’s conference call. At this time, all lines have been placed on a listen-only mode until the question and answer session of today’s conference. Also, the conference call is being recorded; if you have any objections you may disconnect at this time. Now at this time I’d like to turn the conference call over to your speaker, Mr. Mike Watts. Thank you sir, you may begin.

Thank you Barry, and good afternoon everyone. On behalf of Hank Nordhoff, Gen-Probe’s Chairman, President and CEO, and Herm Rosenman, our Senior Vice President of Finance and CFO, as well as the rest of the Gen-Probe team, I’m pleased to welcome you to this conference call to discuss our Q3 2007 financial results. The press release announcing our results was issued today just after 4:00 pm ET, and is posted on our website at www.gen-probe.com. In our call today, Hank will first provide an overview of our top-line performance in the quarter. Herm will then review our detailed results and updated guidance, then will take your questions. Before we begin, let me first review our safe harbor policy. Forward-looking guidance, financial or otherwise, is only provided on conference calls or in our press releases. Any statements in this conference call about our expectations, beliefs, plans, objectives, assumptions, or future events or performance, are not historical facts, and are forward-looking statements. These statements are often, but not always, made through the use of words and phrases such as believe, will, expect, anticipate, estimate, intend, plan, foresee, could, should and would. For example, statements concerning 2007 financial guidance, financial condition, regulatory approvals and timelines, possible or assumed results of operations, growth opportunities, industry ranking, plans, and objectives of management, are all forward-looking statements. Forward-looking statements are not guarantees of performance, they involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Factors that might cause such differences include, but aren’t limited to, those discussed in our SEC filings, including our report on Form 10-K, for the year ending December 31, 2006, and all subsequent periodic reports. Copies are available on our website, at www.sec.gov, and on request from our IR department. Gen-Probe assumes no obligation and expressly disclaims any duty to update any forward-looking statements to reflect events or circumstances after the date of this call, or to reflect the occurrence of unanticipated events. With that administrative detail out of the way, I’ll turn the call over to Hank Nordhoff, Gen-Probe’s CEO.

Thanks Mike, and good afternoon everyone. As described in our press release, Gen-Probe had a very good Q3. We set new records in both clinical diagnostics and blood screening product sales, as well as total revenues. As a result, we are again raising our 2007 financial guidance for revenues and earnings per share. Before I begin the discussion, I’d like to thank you for your many calls and concern surrounding the recent wildfires in San Diego. The fires were certainly frightening for hundreds of Gen-Probe employees, including several executives on this call, who were forced to evacuate their homes. In fact, we converted the training facility at our main headquarters campus, which was not in a fire zone, into a home away from home for about 60 employees and family members for a couple of nights. Thankfully, and in contrast to the fires four years ago, no employees lost their homes. As for the business, we do not expect any lasting disruption or negative financial effect from the fires. Our blood screening manufacturing plant in the town of Rancho Bernardo was closed for a few days last week, but we resumed full operations yesterday, and expect to be able to catch up on our productions and shipments over the next several weeks. Now let me review our record Q3 results. When I’m finished, I’ll bring you up to speed on one of our key R&D programs, our initiative to develop a test for human papillomavirus, or HPV, and also provide brief updates on our prostate cancer and Millipore initiatives. Product sales in Q3 were $97.4 million, another quarterly record, and 17% above last year. Non-product revenues were also healthy, contributing to record total revenues of $101.7 million. Total revenues were up 10% over Q3 2006, even though last year’s results…

Thank you Hank and good afternoon everyone. Since Hank already discussed product sales I’ll start with collaborative research revenues which were $3.1 million for the third quarter of 2007, more than double the 1.5 million we recorded a year ago. This increase resulted primarily form higher funding by Novartis, with reimbursement from 3M, Millipore, and the US Department of Defense contributing as well. Looking ahead to the forth quarter we expect collaborative research to increase on a sequential basis based primarily on milestone payments we expect to receive from our partners. Royalty and license revenues were 1.2 million in the third quarter a big decrease compared to the $7.3 million in the prior year period. Royalty and license revenues were high in the third quarter of 2006 based on an aggregate $6 million of revenue we recognized from Bayer and from Tosoh. Without these payments, royalty and license revenues were essentially flat year over year and we expect this line to remain sequentially flat at around a million dollars in the fourth quarter of 2007 as well. Now let me turn to gross margin on product sales which was 67.3% in the third quarter, down considerably from 70.9% in the prior year period, which was a recent high. This decline in the gross margin percentage was primarily to the negative impact of instrument sales. As Hank said, we sold$ 3.2 million of TIGRIS instruments to Novartis in the quarter, compared to about 2 million of instruments and spare parts in the prior year period. In addition, compared to recent quarters, we sold roughly an incremental $3 million of instrumentation to currently new clinical diagnostic customers and these were sold at a very low margin. If you do the math, this incremental $4 million of instrument sales decreased our quarterly gross…

Thanks Herm, we’re happy to take your questions now. For Q & A we’re joined by Carl Hull, executive VP and COO, Bill Bowen, senior VP and general counsel, Steve Kondor, senior VP of sales and marketing, Lynda Merrill, VP of industrial relationships, Harry Rittenhouse, director of cancer research and Kevin Heardy, senior director of finance. In order to ensure broad participation in the Q & A session please be courteous and limit your questions to one plus a follow up, then jump back into the queue. Operator we’re ready to take the first question

(Operator instructions). And your first question comes from David Lewis of Morgan Stanley

Good afternoon. Hank, I wanted to start off with equipment sales. They were a little heavier than obviously you or we were anticipating. I was wondering if this was an anomaly or it’s a trend, so is there any sort of additional feedback you could provide in terms of the magnitude of theses sales, whether the relative rate hat was in blood screenings, what was in clinical diagnostics. You also mentioned some of these were new and some were re-up users. I wonder if any of these users that bought a second system were diagnostic customers, so any detail you can give us on equipment would be very helpful.

I’ll take the first of those fourteen questions. I think it really is an aberration, and I think the instruments on comparative basis compared to an average month we sold more on the diagnostic side than we did on the blood screening side. I wouldn’t expect that to continue.

Okay and then international has gotten more attention here in the last coming quarters. I guess you’re talking about an increase in sales in marketing. Can you give us a more specific idea of what you’re envisioning for international as we head into 2008 and 2009, and what kind of steps is the company willing to take to accelerate their business international perhaps coming off of the HP launch in the back half of the year?

We probably have about 15 people in international right now, most overseas; we have a staff here of course. And next year, and I’ll defer to Steve on this, but I think we’re planning on adding about five or so in Europe primarily. Steve?

That’s correct Hank. David we are planning to add about five or so in Europe obviously to support the eminent launch of HPD, we have people today in the Germanic speaking countries, we’ll be adding folks in Italy and Spain and France and other countries in Europe as well. We have a presence in the UK and we’re supplementing that, our business continues to grow there on the STD side as well. So what we want to do is make sure we’re well positioned in the countries to support not only our new products such as HPV PCA3, but the emerging and growing STD business in Europe as well.

Steven, just following up to that, you have sort of a dominant US GC position. Overseas is certainly not dominant and one of your competitors has placed a dramatic number of boxes or midrange systems overseas. What are your expectations for the go to the take market shares overseas, specifically in DC?

Well we have done that this year pretty well and that’s what’s buried in the numbers here in terms of the STD growth. We’ve placed seven TIGRIS’ in Europe alone this year and so on the high volume lab sector we’re targeting those with obviously a differentiated platform, the TIGRIS. In the mid volume range and the lower volume range, that’s where we anticipate that Panther will be able to come in and garner more (inaudible)

Okay and then maybe one last question for Carl or for Hank. You’ve talked about research and development leverage, or we have talked about research and development leverage throughout this year, could you give us an update on you’re likelihood or willingness to grow your research and development pipeline through acquisition versus the PNL and any sort of increase in activity on the business development front you’ve had in the last six months.

Let me start off, and then I’ll give it to Carl, so you get familiar with Carl’s voice. We don’t anticipate a big hike next year. We’re always looking for acquisitions, I think we discussed in this phone call just haven’t seen anything yet, can’t really see making an acquisition that will increase R & D expenses. We would like to do something to expand our footprint geographically, specifically in Europe to get us a little more infrastructure over there.

David, it’s Carl. I think that we feel comfortable with our level of R & D spend as it has been in the past couple of quarters, nothing the exceptions that Herm mentioned this quarter for the one time, HPV expenses. I think that we’re doing our best to focus those dollars on the key programs to accelerate those programs individually and as a group and I feel that there’s not a need for an internal or organic expansion of that spin level right now.

Great. Well Carl I think your voice is going to give Hank a run for his money. Alright thank you.

Thank you your next question comes from Quintin Lai of Robert W. Baird

Good afternoon guys. This is actually Matt for Quintin. Congratulations on the quarter

Thank You.

Just a couple of quick questions. As the cash balance continues to rise you kind of spoke about not seeing anything interesting in the way of acquisitions, but could you provide a little color on what your plans might be to put that cash to work?

We are looking assiduously at candidates to acquire to broaden our businesses space both geographically and in a product sense. We’re not anticipating paying a dividend and we are not anticipating buying back our stock. But we do continue to generate an awful lot of cash and we expect to find a useful use for that.

Would it be fair to say that it might be in the form of just taking on other projects or investing more in these shots on goal as you guys sometimes say?

I think we’re reluctant to increase our R&D spending as percentage of revenues so I think it’s going to be more external than internal.

Great. Thank you for that. And just in recent weeks we’ve gotten a lot of press on health care acquired infections, particularly MRSA. Just wondering of you guys could provide some more color on where that stands right now with 3M and how that’s developing for you guys.

We’re moving along beautifully, right on schedule. We remain very enthusiastic about it, I just heard it on the news, I think it was Illinois; they’re going to start testing patients upon admission to hospitals as way to control and combat MRSA infections.

Yeah just to add to that Hank, we also have on target with regard to our feasibility milestone, we have a milestone to reach feasibility for MRSA and we’re on track with that so everything is good news there.

Thank you very much. Congratulations again.

Thank you your next question comes from Bill Quirk of Piper Jaffray.

Thanks good afternoon.

(In unison) Good afternoon, congratulations. Congratulations on your new son.

Oh thank you. Thank you very much.

Thank you. Couple of quick questions Hank: So thanks very much for, first of all, addressing HPV and the timelines and you are right so, do we, can we say at this point that we can pretty much put this three year prior to filing issue to bed? So to speak.

Sorry I don’t understand.

So the question is, Hank you mentioned that we have had some very constructive conversations with FDA, over the what data will be required to file for HPV? And so what I’m trying to get to here is a level of confidence that we are not going to say, go the di-gene pathway. Or we are going to have the three year follow-up data prior to submission

I think we have been probably overly conservative in the past, particularly compared to one of our potential competitors. And I think we are getting more comfortable and I think you can expect a more reasonable estimate of the amount of time it is going to take to get to the market.

OK, fair point. You may have mentioned this, I am sorry, I may have missed it earlier but did you talk about the number of donations we have screened thus far vis-à-vis the first yield case.

Yeah I think we did it is about 200 and...

About 260 Bill.

260 Okay, great.

Pretty much on schedule. So I’ll go on a limb and say that, I would expect that we’d get the second one certainly by the end of the year.

Sounds good that certainly would be

That is a limb that Hank, that he has just perched himself on

I’ll make sure I will refer to the disclosure statement Mike, thank you guys.

Congratulations again.

Thank you, next question comes from Peter Lawson, of Thomas Weisel.

I wonder it you could give us an update on the prostate cancer initiative; where it stands with the FDA? If it is still going to be urine based?

Harry can I turn that over to you?

Yes, the strategy remains the same regarding PCA-3, it will be urine based. We are developing a more automated technology form for the assay, which is going to improve the analytical performance. The clinical research studies are being expanded and continuing so we are getting better definition for what the clinical trial design is going to look like.

When is this, a filing, expected with the FDA?

We still have not definitively decided on that peter we’re still going through the analysis. I think as I read earlier in my prepared comments, it is a terrific product it has generated a huge amount of enthusiasm in Europe as well as in the US and I think the tandem of PCA-3 and TMPRSS will be very, very, compelling for the urologist.

I should add that our strategy is a portfolio of prostate cancer tests that will include tests for treatment selection and prognosis. The studies with TMPRSS are going quite well and independent studies are showing positive results which make us more confident that TMPRSS with a fish test or a urine test, probably both, are going to be very useful for treatment selection and prognosis

I wonder if you could talk to HPV tests; how you are going to set yourself against the competition? What’s the competitive advantage for your sales force?

Hi Peter, I think the major advantages you will see for our HPV assay will be predicated on our ability to automate the assay in high volume, and do so with a standard and familiar Aptima assay format. This will really distinguish us from everybody that is out there today. Of course, underlying that, will be analytical performance that is at least as good as what is out there on the marketplace today. And we frankly feel, as you see the data unfolding over the course of the next couple scientific meetings, some significant improvements are possible using our design of the assay. And I think, at the end of the day those two things will be more that sufficient to hang our hat on in this marketplace.

Okay. And just finally I wonder if you could just break out the revenue by geography and if there was any FX benefit this quarter?

It is… Outside the US continues to approximate 15% Peter, as it has pretty much every quarter and certainly every year over the last several years. The FX effect on the quarter was insignificant.

Okay, thank you so much.

Thank you Peter.

Thank you, next question comes from Zarak Khurshid of Caris and Company

Hi guys, thanks for taking my question. You may have already covered this, I apologize, the level of interest income, is that sustainable for the foreseeable future?

Well that’s going to depend on the rates which we’d all like to see come down potentially another quarter of a point pretty soon, they talk about. So the rates may come down a bit, but the cash is building nicely so I think it is sustainable; unless as Hank and Carl have mentioned, we do find an acquisition that makes sense for Gen-Probe. We have not yet but it may come along at some point.

Right, great. And then, sorry to harp on the PCA-3 business but last quarter it sounded like you were getting close to making a decision on the marker strategy. I guess my question is what exactly has changed since then on that front?

I don’t want to sound flippant. But we are getting even closer and really nothing has changed we are looking at the cost, at the advantages of doing this, of doing it simultaneously with the introduction on TMPRSS and our analysis is not yet finished.

Perfect, thanks. And then you mentioned significant unit volume remaining with… within pace. How much unit volume was in PACE at the start of the year, and would you expect similar rate of cannibalization going forward in the STD business?

Steve?

We anticipate that we will be at 80% revenues being APTIMA, 20% being PACE. And in terms of the units we still have about 40% of the units, the testing volume, at the end of this year being PACE.

Okay, great. And I just wanted to say best wishes to the Gen-Probe family in light of the fire.

Thank you very much.

Thank you, your next question comes from Dan Leonard of First Analysis Corp.

Good afternoon, a couple of things. One, for your fourth quarter revenue outlook; you mentioned that you pulled some business forward from Novartis into the third quarter. How much was that? The West-Nile Virus business that you pulled forward.

Well we didn’t pull it forward; they brought it forward. And I think that was about $2 million of product revenue.

Okay, so that piece, plus the instrument aberration in the quarter is what would get you to the lower Q4 revenue number?

That’s basically it

Okay, and then on the expenses for the fourth quarter, you mentioned a number of different expense items that would be higher that maybe we were originally looking for to bring your earnings lower than the street. Can you ordinally rank those for me?

I think I mentioned one, which was sales and marketing expense related to our European launch of HPV starting with Europe for that next year. That was the only one that I mentioned that would be higher.

I thought you mentioned sequencing for HPV that might increase costs and other things as well. Is that not true?

Yeah, that will be next year as we go into the HPV clinical trial.

Okay, thank you very much

Thank you Dan.

Thank you, your next question comes from Bruce Cranna of Leerink Swann.

Good afternoon guys

Hey Bruce.

A lot of this stuff has been touched upon. So I guess I just want to go through some of the finer points. Hank, just again on --- I think this question was asked but I didn’t think I heard and answer on the TIGRIS sales, the instrument sales, on the clinical side in a quarter. I understand it was sort of an aberration, but the comment about a portion of that and maybe a good portion being to existing accounts. Those -- we are talking about parts or are these actual instruments and accounts running more than one instrument?

These are actual instruments.

So this is a situation where an account needs greater volume so they are starting another TIGRIS.

No it is some of the accounts had the TIGRIS instrument there and decided to buy it. And it is really a sense of a long-term commitment to the instrument and to Gen Probe as a supplier.

Okay, and a couple quarters ago I seem to recall you parted with a worldwide base number on TIGRIS. Do you happen to have that number again?

Installed base? Bruce?

Yes sir

Worldwide. Why not call diagnostics see if they have that information

Just about half and half I would say. 100 to 110 or so.

Yeah, I need guidance.

That’s ballpark Bruce.

Is that pretty close to the number we gave you the last time Bruce?

That’s not bad I think it was 160 on the first quarter so that sounds pretty good.

Bruce if you come to our analyst’s day we will give you a more precise update.

I’ll hold you to that Mike. Then again I… Just on PCA-3, I guess Hank, so it sounded to me like maybe you were taking your foot off the gas a little bit due to HPV spending. Is that not sort of… Did I not get the right read on that, on PCA-3?

I can’t argue with that, but I would say that we are probably putting the pedal to the metal in terms of the analysis and all the implications of going forward with the US IBD as PCA-3 is currently formulated.

As I recall you guys, at one point, were getting some funds from the DoD; is that still the case?

Yes

And will that move into ‘08 as well you think?

Those funds, probably not

Could that be re-upped I guess is what I’m saying?

It could be, but I think it is probably unlikely to occur next year.

Okay, and last sort of persnickity question from me. In general your sense on the HPV side is it too early to talk about your “all a go” cost ’08 versus ’07 or do you care to comment on that at all, on which way that might move?

It’s too early Bruce.

Okay, just thought I’d ask. Alright, thanks guys

Thank you sir.

Thank you, your next question comes from Spencer Nam of Summer Street Research Partners

Hi, thanks for taking my questions, just a couple of quick questions. On the HPV screening side, hank you were kind enough to give us a little more color on the future. When do you recognize the $10 million from Novartis, is that when you find the second case? Or is that when you get the FDA go-ahead?

It is the FDA approval on the ULTRIO assay on TIGRIS.

Okay, I appreciate that. And then you also mentioned hank in your prepared comments that PCA-3 is ramping up nicely; can you give us a little more details on that maybe, if possible. What are we seeing, both here and the Europe, how are the physicians receiving the tests and what sort of test scale are we talking about?

Let me turn it over to Steve who can address all that

Spencer, we said in the last call we anticipated a couple million dollars in revenue for PCA-3 between the US ASR product and the Europe CE approved product so that’s staying about that, we have seen. And we have had recent activity in Europe with regard to our market development program creating awareness among urologists about the availability of the PCA-3 test and its clinical utility. I think we are starting to see some up tick on that, particularly in Europe, as well as, I think, through the halo effect here in the United States with our ASR labs. So unit volume at these labs is starting to increase and we expect that to continue throughout the year.

And in terms of the labs that they involved in using the PCA-3, we don’t expect such a growth in the number of labs in 2000... The rest of the year and going forward, is that fair?

That is correct Spencer.

Great, thank you.

Thank you.

Okay, your next question comes from Tycho Peterson of J.P. Morgan

Hi, good afternoon.

Hi Tycho.

You have talked in the past, you have at least given some limited color about potentially the distribution strategy for PCA-3. Can you give us a sense of, you know, what point you make the decision. Is it over the next year when you decide you will partner with a Labcorp or Quest in terms of pushing the tests onto the market?

Yeah it will be once we make our decision regarding PCA-3 how we are going to go forward. It will be within a year of making that decision to allow ample time before launch.

Okay, you talked about some of the TIGRIS placements on the diagnostic side in Europe, you know. Can you give us a sense of whether these are competitive wins and the underlying question there is: Is there still some lingering talk about some of the Chlamydia strains and potentially the N2000’s inability to pick them up. And I’m just wondering: A, how often are you having bake-offs and B, whether there are competitive wins happening?

Yeah Tycho, of the seven new TIGRIS placements we have in Europe this year, five of those are competitive takeaways actually. And two are just STD programs that have increased their volumes and have ordered additional TIGRIS’. So that’s the market that we are targeting over there in Europe.

Okay, great. And just sell me on the Novartis warranty issues, does that work through this quarter? I’m not sure if you commented on how quickly that will carry through.

I think about half of it goes through this quarter.

Okay, great. Thank you very much

You’re welcome.

Thank you, next question comes from [Doug Shankle - Cohen]

Hi, good afternoon.

Hi Doug.

On follow-up on much of your R&D commentary. I believe you previously talked about commencing a U.S. pivotal trial in HPV by year-end. I apologize if you talked about this already, but is this still the case?

We probably would have been able to do that Doug, were it not for the change in the genotyping requirement. We expect now the initiation to be in the first quarter of next year.

Okay. Thank you. I know there was some news on the Japan Green Cross bid. Is there any more detail you can provide on that bidding process and how that unfolded?

I don’t think there’s much that we can say on it.

Okay, and one last housekeeping question. Any chance you could provide us with the impact on an absolute dollar basis of the contribution of West Nile virus pricing compared to last year?

I’m looking around the table and everybody is shaking their head. So I guess I’ll go with the consensus on that one Doug.

Alright, well maybe we can talk about it after the call. Thanks for taking my questions.

Thank you. Your next question comes from Michelle Ha of Ferris Baker.

Hi good afternoon. Congratulations on the quarter. Your guidance assumes on the previous question that the $2 million in product revenue from Novartis as well as equipment sales will not recur in Q4. What is, I hadn’t modeled this much equipment sales, what sort of drives that, or what can we do to anticipate that better going forward?

I would not anticipate additional instrument sales at that level.

Yeah Michelle, they were truly one time, as Hank indicated in the prepared remarks.

Okay, and going to clinical diagnostics and blood screen revenue, can you give us a number there of what your market share is now compared to what it was a year ago in your STD franchise and also comment more about the international revenues from ULTRIO?

Michelle, this is Steve, I’ll take it, your question regarding clinical diagnostics and market share. We believe right now our market share worldwide to be about 50%, that’s both in terms of revenues as well as in terms of tests. In terms of dollars, I mean, excuse me, in terms of U.S. market, we are at about 60% of the market, again in terms of revenues as well as in terms of tests. And we are, according to the figures that we have seen, our market is growing, we’re growing at a little over twice the rate of the market.

Great, thanks a lot.

Operator, I think we may have time for one or possibly two more questions.

Okay. Your next question comes from Jon Wood of Banc of America.

Hey, thanks a lot. If you were to get an opportunity to do a deal in Europe, to boos the infrastructure there, how sensitive is management to near-term PNL dilution?

I think with the right opportunity Jon, we would be able to withstand some near-term dilution, with the offset of high potential of accretion.

Okay. And then, given it doesn’t seem like you’re too excited about any other diagnostic technology out there, is a deal likely to target a distribution-type asset, or could you comment on, what kind of asset you would be interested in?

Well, we think that the technologies we have are pre-eminent in the field, but there are certain technologies that we don’t have, that would be interesting. As an example, in relation to HPV genotyping, sequencing. Some of that would be nice to have. So I couldn’t see us going after a distributor, we’d want to get more than just that.

Okay. One quick one. The American Red Cross ULTRIO post-marketing study, is it safe to say that organization wouldn’t adopt ULTRIO until that’s complete?

You know, probably, I hate to duck this one, but the best people to talk to would be those at (inaudible).

Okay. And then when do you, how long do you think an American Red Cross specific study would progress?

Well, one is just to get them familiar with the assay and secondarily is to pick up yield, in addition to the yield we’re already getting from our own independent study. So that’s a tough call. I would say, yeah, less than a year, six months.

Okay, thanks a lot.

You’re welcome.

Thank you, your last question comes from Zarak Khurshid of Caris & Co.

Hi guys, thanks for taking the follow up question. With respect to the HPV trial, do you have a ballpark estimate for the cost there, and then maybe if you could quantify the incremental uptick for sequencing.

It’s Carl. We don’t really comment on the detailed cost at an individual program level. Suffice it to say that our budget and our plans for this program are for one of the largest clinical trials in Gen-Probe’s history. As you look at other data that have been disclosed about the investments that other competitors have made here, we would consider our spending to be consistent with that. I can’t really comment on the uptick related to sequencing requirements because there’s some puts and takes related to that, and we’re still finalizing our approach there.

Great, thank you.

Operator, we do have some brief closing remarks.

Okay.

Well, I’d like to thank you all for your questions, and to wrap up, Gen-Probe had a strong third quarter, with solid underlying growth from both clinical diagnostics and blood screening and earnings per share ahead of expectation. In addition, we made important progress on expected value drivers, including our yield study for the PROCLEIX ULTRIO assay, and our HPV development program. Before we sign off, Mike has asked me to remind you that our annual Analyst’s Day is planned for the afternoon of Thursday, November 29, at the Loews Regency in New York. Please watch your email for more information, and we look forward to seeing many of you there. Thank you for your time and attention today and please contact us if you have any follow up questions.